{"id":110240,"date":"2026-06-29T12:12:02","date_gmt":"2026-06-29T12:12:02","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/vivosim-presents-data-showing-superiority-to-competition-in-nam-liver-tox-prediction-at-european-toxicology-meeting\/"},"modified":"2026-06-29T12:12:02","modified_gmt":"2026-06-29T12:12:02","slug":"vivosim-presents-data-showing-superiority-to-competition-in-nam-liver-tox-prediction-at-european-toxicology-meeting","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/vivosim-presents-data-showing-superiority-to-competition-in-nam-liver-tox-prediction-at-european-toxicology-meeting\/","title":{"rendered":"VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting"},"content":{"rendered":"
\n

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the \u201cCompany\u201d or \u201cVivoSim\u201d), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced that data demonstrating the power of its advanced 3D human tissue models will be featured in two presentations at the European Society of Toxicology\u2019s annual conference.<\/p>\n

The presentations collectively showcase the best-in-industry predictive power of VivoSim’s proprietary AI-enabled NAMkind\u2122 Liver and NAMkind\u2122 GI platforms. In liver toxicology testing, across a set of compounds where animal models and traditional methods provide 50-65% sensitivity, VivoSim\u2019s models provided >90% sensitivity at detecting true positives for liver toxicity. Whereas current methodologies including animal in vivo<\/em> testing can result in >10% false positives (wrongly predicted to have liver tox when they do not, causing rejection of a viable drug candidate), VivoSim\u2019s liver toxicology methods result in fewer than 5% false positives.<\/p>\n

These powerful results help VivoSim clients avoid expensive mistakes in drug development, at a time when the industry is undergoing a shift in preclinical safety evaluation. “With a heavy push from the US FDA, the pharmaceutical industry is moving away from traditional animal testing toward high-fidelity, human-relevant alternatives,” said Keith Murphy, VivoSim Executive Chairman. “As our newest data show, using AI-informed models in highly accurate tissues, we detect the problems that pharma typically misses. When a pharma has a miss, the cost to them is many lost years and $50M – $200M, so strategic-thinking pharma executives are taking notice of the availability of better tools.”<\/p>\n

The United States Food and Drug Administration (FDA) is actively encouraging human-relevant NAMs in place of animal studies, a push that is resulting in greater pharma demand for new technologies. After presenting its April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies, the FDA recently reported that it is meeting its goals for stimulating pharma uptake of these new models. VivoSim\u2019s novel models offer perhaps the most predictive tool to make FDA\u2019s vision a reality.<\/p>\n

VivoSim\u2019s superior results are achieved by a combination of the best biological model with the most representative primary human cell types, leveraging multiple endpoints as readouts for best prediction, and training AI prediction models with multiple endpoints that provide a rich data set, yielding high prediction accuracy. In addition to testing traditional oral pill small molecules, VivoSim is establishing competitive advantages across new biotech modalities such as antibodies, siRNA, and gene therapies. Adding to the data supporting its industry leadership in small molecules as outlined above, the company has done extensive testing of Antibody Drug Conjugates (ADCs), one of oncology\u2019s fastest-growing modalities, with comparable accuracy results in terms of predicting the clinical profiles of ADCs for liver toxicity and diarrhea. Globally, hundreds of ADC candidates are now in active clinical development against over 50 molecular targets \u2014 41 of them already in Phase III \u2014 and the pipeline remains overwhelmingly oncology-focused, led by HER2- and TROP2-directed programs in breast and lung cancer. Therapies still fail in human trials, most often on safety or efficacy. VivoSim\u2019s mission is to close gaps in the ability to predict outcomes before a drug enters expensive clinical trials.<\/p>\n

\u201cThese results show our human-relevant models let developers move from detecting liabilities to predicting risk,\u201d said Amar Sethi, MD, PhD, Chief Scientific Officer of VivoSim. \u201cWhether we are unraveling the cause of TKI-induced diarrhea or guiding the design of safer, more effective ADC linker-payload combinations, our multi-endpoint profiling gives teams the translational signatures they need to retire toxic liabilities long before a single patient is dosed.\u201d<\/p>\n

Overall, the findings show that the Company\u2019s human-relevant models can predict liver and gastrointestinal toxicity \u2014 for both traditional small molecules and complex antibody-drug conjugates (ADCs) \u2014 with accuracy that tracks real clinical outcomes. The data are being presented at The 23rd International Congress of the European Society of Toxicology In Vitro (ESTIV 2026) in Maastricht, the Netherlands, which takes place from June 29 to July 2, 2026.<\/p>\n

Key highlights of the presented data demonstrating VivoSim\u2019s ability to achieve definitive translational signatures across complex organ systems:<\/strong><\/p>\n